Granules India, a Rs. 1,200 crore pharmaceutical major from Hyderabad, has received US FDA approval for ibuprofen tablets USP, 400 mg, 600 mg and 800 mg.

C Krishna Prasad, chairman and managing director said, “It's my pleasure to state that US FDA completed the review of ibuprofen ANDA filed by us and ha given its final approval. It will further strengthen our base business and enable us to increase our product offering to our customers in USA.”

Granules global presence extends to over 300 customers in 60 countries through offices in India, US, UK, China and Colombia. It has the largest PFI facility in the world with an industry leading 6 ton batch size.